Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: Prospective randomised trial in Finland

BMJ (Online)

Volumn 345, Issue 7886, 2012, Pages

  Leinonen, Maarit K ^a   Nieminen, Pekka ^b   Lönnberg, Stefan ^a   Malila, Nea ^a,c   Hakama, Matti ^a,c   Pokhrel, Arun ^b   Laurila, Pekka ^b   Tarkkanen, Jussi ^b   Anttila, Ahti ^a  

^a FINNISH CANCER REGISTRY   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA IN SITU; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOLOGY; DNA SCREENING; FEMALE; FINLAND; FOLLOW UP; HEALTH PROGRAM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMA VIRUS; POPULATION RESEARCH; PRECANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADENOCARCINOMA; ADULT; AGED; COLPOSCOPY; CYTOLOGICAL TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84870710146     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e7789     Document Type: Article

References (23)

1. International Agency for Research on Cancer. Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans. IARC Press, 2007.
2. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45:2640-8.
3. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data [correction in: BMJ 2009;339:b3115]. BMJ 2009;339:b2968.
4. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(suppl 10):K29-41.
5. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomised setting. J Natl Cancer Inst 2009;101:1612-23.
6. Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P. Alternative technologies in cervical cancer screening: a randomized evaluation trial. BMC Public Health 2006;16:252.
7. Working group of human papillomavirus diseases. The National Institute for Health and Welfare. Report 28/2011. www.thl.fi/thl-client/pdfs/94d6f45d- 22e1-4b53-b615-2eea48d90e1c.
8. Lönnberg S, Leinonen M, Malila N, Anttila A. Validation of histological diagnoses in a national cervical screening register. Acta Oncol 2012;51:37-44.
9. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97. (Pubitemid 47598401)
10. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomized controlled implementation trial. Lancet 2007;370:1764-72. (Pubitemid 350137476)
11. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;377:a1754.
12. Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 1995;85:1017-21.
13. Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009;125:525-9.
14. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener HG, Herbert A, Daniel J, von Karsa L. European guidelines for quality assurance in cervical cancer screening. Office for official publications of the European Communities, 2008.
15. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.
16. Lynge E, Anttila A, Arbyn M, Segnan N, Ronco G. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Eur J Cancer 2009;45:2714-21.
17. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-57.
18. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial [correction in: Lancet Oncol 2009;10:748]. Lancet Oncol 2009;10:672-82.
19. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88.
20. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
21. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, et al. Regression of low-grade squamous intraepithelial lesions in young women. Lancet 2004;364:1678-83. (Pubitemid 39458143)
22. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
23. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.